Patents Examined by Elly-Gerald Stoica
  • Patent number: 11732050
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: August 22, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Patent number: 11725039
    Abstract: The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or bispecific comprising said TCR, said cell, said clone or said vector; use of said TCR or said cell or said clone or said vector or said pharmaceutical composition or bispecific to treat cancer; and a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition or bispecific comprising said TCR.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: August 15, 2023
    Assignee: University College Cardiff Consultants Ltd.
    Inventors: Andrew Sewell, Garry Dolton
  • Patent number: 11725034
    Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.
    Type: Grant
    Filed: March 31, 2022
    Date of Patent: August 15, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi Wu, Tong Zhang, Maria del Pilar Molina-Portela, Eric Smith, Chia-Yang Lin, Thomas Craig Meagher
  • Patent number: 11718655
    Abstract: Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.
    Type: Grant
    Filed: April 8, 2022
    Date of Patent: August 8, 2023
    Inventors: Margaret Karow, Deborah Moore Lai, Dheeraj Tomar, Parker Johnson, Raphael Rozenfeld, Ronan O'Hagan, Huawei Qiu
  • Patent number: 11709165
    Abstract: [Object] To provide a novel examination method for a cancer treatment effect, screening method for a peptide for a cancer vaccine, and peptide and composition for inducing an immune response against cancer. [Solving Means] Provided are an examination method for a cancer treatment effect and a screening method for a peptide for a cancer vaccine each including detecting an antibody against a cancer/testis antigen or an anti-p53 antibody in a sample. It is suitable that an anti-XAGE1 antibody (IgG and/or IgA) be detected, or an anti-NY-ESO-1 antibody (IgG) be detected. Also provided are a novel peptide and novel composition for inducing immune responses against cancer.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: July 25, 2023
    Inventors: Mikio Oka, Eiichi Nakayama, Yoshihiro Ohue, Koji Kurose
  • Patent number: 11702472
    Abstract: The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: July 18, 2023
    Inventors: Prasad S. Adusumilli, Michel Sadelain, Dimiter S. Dimitrov, Yang Feng
  • Patent number: 11701357
    Abstract: Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a targeted therapy agent. Also, disclosed a pharmaceutical combination comprising a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor, or a targeted therapy agent and the use thereof.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: July 18, 2023
    Inventors: Nan Hu, Lai Wang, Jing Song, Tong Zhang, Kang Li, Lusong Luo, Min Wei, Zhiwei Wang, Yunhang Guo
  • Patent number: 11703508
    Abstract: Methods are disclosed for treating ovarian tumors and ovarian and pancreatic cancers using computed and normalized relative ratios of plasma levels of phospholipids, particularly lysophosphatidylcholine, lysophosphatidylethanolamine, phosphatidylcholine, phosphatidylethanolamine and sphingomyelin.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: July 18, 2023
    Assignee: The Feinstein Institutes for Medical Research
    Inventor: Junhwan Kim
  • Patent number: 11696927
    Abstract: Disclosed are compositions and methods for directing NK cells to the bone marrow through the use of PM21 particles.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: July 11, 2023
    Assignees: University of Central Florida Research Foundation, Inc., Research Institute at Nationwide Children's Hospital
    Inventors: Alicja Copik, Jeremiah Oyer, Nitin Chakravarti, Dean Anthony Lee
  • Patent number: 11693009
    Abstract: Described herein are methods and systems for detecting and/or distinguishing irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD) and celiac disease. The methods and systems can utilize the detection of anti-CdtB antibodies and/or anti-vinculin antibodies to detect IBS, distinguish IBS from IBD and/or celiac disease. Further described are methods for selecting a therapy to treat IBS, IBD or celiac disease.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: July 4, 2023
    Assignee: Cedars-Sinai Medical Center
    Inventors: Mark Pimentel, Christopher Chang
  • Patent number: 11685780
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment. In some embodiments, the tumor target antigen is B7H3.
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: June 27, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Chad May, Robert B. Dubridge, Maia Vinogradova, Anand Panchal
  • Patent number: 11672849
    Abstract: Provided are compositions, optionally pharmaceutical compositions, that include a plurality of exosomes generated from stem cells, optionally ESCs and/or iPSCs, that have been modified to express a granulocyte-macrophage colony stimulating factor (GM-CSF) polypeptide, optionally a human GM-CSF polypeptide. Also provided are methods for employing the presently disclosed compositions for preventing and/or inhibiting tumor growth in subjects in need thereof, for preventing and/or inhibiting metastases in subject in need thereof, for inducing anti-tumor immune responses in subjects, and uses of the presently disclosed compositions for prevention and/or treatment of tumors and/or cancers and for the preparation of medicaments for treatment of tumors and/or cancers.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: June 13, 2023
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: John W. Eaton, Kavitha Yaddanapudi, Chi Li
  • Patent number: 11674967
    Abstract: A new, stable trimeric TNF? structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNF?/TNFR1 interaction. Membrane-bound TNF? is not affected in its ability to signal through TNFR2, and thus the new structure of TNF? may be used in therapies which do not significantly raise the risk of infection or malignancy.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: June 13, 2023
    Inventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Boris Kroeplien, Stephen Edward Rapecki, Timothy John Norman, Graham John Warrellow, Tracy Lynn Arakaki, Alex Buntin Burgin, William Ross Pitt, Mark Daniel Calmiano, David Andreas Schubert, Daniel John Lightwood, Rebecca Jayne Munro
  • Patent number: 11673962
    Abstract: Methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject, the method comprising a step of administering a recombinant hGMCSF antagonist to the subject, wherein said administering inhibits or reduces the incidence or the severity of immunotherapy-related toxicity in said subject, are provided. An hGMCSF antagonist for use in methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject also are provided.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: June 13, 2023
    Assignee: HUMANIGEN, INC.
    Inventors: Cameron Durrant, Dale Chappell
  • Patent number: 11673965
    Abstract: The present invention provides a pharmaceutical composition and a treatment method to be combined with radiotherapy, for treatment of triple negative breast cancer. More specifically, the pharmaceutical composition comprises a PD-1 blockade and a PI3K? ? inhibitor, and it has excellent effects of inhibiting tumor and enhancing immunity by combining the PD-1 blockade and PI3K? ? inhibitor with radiotherapy, compared to single therapy of each therapeutic agent.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: June 13, 2023
    Inventors: In-Ah Kim, Min-Guk Han, Bum-Sup Jang, Mi-Hyun Kang, Won-Ick Chang
  • Patent number: 11667687
    Abstract: Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first peptide mask (PM1), a third cleavable moiety (CM3), a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1, and the CM3 is positioned between the PM1 and CP1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.
    Type: Grant
    Filed: March 16, 2022
    Date of Patent: June 6, 2023
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Sayantan Mitra, Nicole G. Lapuyade, Hikmat Haizar Assi, Madan M. Paidhungat, Dylan L. Daniel, Erwan Le Scolan, Walter A. Bogdanoff, Na Cai, Hsin Wang, Alexey Yevgenyevich Berezhnoy
  • Patent number: 11661453
    Abstract: The present invention provides methods of treatment for cancer through combination therapy with an agent that inhibits programmed death-1 protein (PD-1) signaling and an agent that inhibits poly[ADP-ribose] polymerase (PARP) signaling.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: May 30, 2023
    Assignee: Tesaro, Inc.
    Inventors: Keith W. Mikule, Kaiming Sun, Jing Yu Wang, Zebin Wang
  • Patent number: 11661455
    Abstract: The present invention relates, in part, to chimeric proteins that find use in various immunotherapies. Particularly, the present invention provides targeted therapeutic agents that modulate the immune system for the treatment of diseases such as cancer.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: May 30, 2023
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Jan Tavernier, Nikolai Kley
  • Patent number: 11655282
    Abstract: The present disclosure relates to chimeric engulfment receptor molecules, host cells modified to include the phagocytic engulfment molecules, and methods of making and using such receptor molecules and modified cells.
    Type: Grant
    Filed: August 11, 2021
    Date of Patent: May 23, 2023
    Inventor: Daniel Mark Corey
  • Patent number: 11654135
    Abstract: Disclosed herein are compositions and methods for treating cancer in a subject. In some embodiments, the methods involve generating an immune response in an individual by inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells. In one embodiment, a method of treating cancer in a subject includes administering amlexanox in combination with immune modulators, such as checkpoint inhibitors, immune co-stimulatory molecules, TLR agonists, and TNFR superfamily agonists. In one embodiment, the checkpoint inhibitors are selected from antibodies against PD-1, PD-L1, and CTLA-4.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: May 23, 2023
    Assignee: Moonshot Pharma LLC
    Inventor: Angela Christiano